On May 13th, Annoroad Gene Technology (Beijing) Co., Ltd. (hereinafter referred to as Annoroad) and MGI Tech Co., Ltd. (hereinafter referred to as MGI) reached a strategic cooperation agreement. The DCS Lab (Omics Frontier Lab) was officially established at Annoroad, marking the entry of both parties’ cooperation into a new stage of development. Zhimin Li, CEO of Annoroad, and Feng Mou, CEO of MGI, witnessed the representatives of both parties sign the agreement.
The two sides will combine their respective strengths and join hands to promote the research and application of genomics (DNA sequencing, abbreviated as "D"), cellomics (Cell Omics, abbreviated as "C"), and spatialomics (Spatial Omics, abbreviated as "S"), build a multi-omics delivery platform, and promote innovation and development in the field of life sciences.
Signing ceremony
Annoroad, as the first corporate user, has participated in the DCS Lab Omics Frontier Laboratory co-construction plan. The two sides will continue to work together to utilize high-quality sequencing service resources, bringing higher standard scientific research services to the general users, and jointly promoting life science research to a higher level and broader fields.
About Annoroad
Annoroad was established in 2012. As a platform-based enterprise in Chinese genome industry, Annoroad has been deeply involved in the two major fields, namely the human medical health and the research on the life science, and has established a professional testing and data analysis platform in the industry, actively promoting the industrialized application of the gene technology and assisting with the development of the life science.In the field of scientific services, Annoroad has conducted extensive scientific research collaborations with domestic and international universities, research institutes, and R&D organizations through multi-omics technologies, and has co-published more than 1,000 articles in journals such as Nature, Science, Cell, and Nature Genomics. Currently, in research areas such as single-cell multi-omics, third-generation sequencing, complex genome assembly, pan-genome assembly, and the exploration of disease molecular mechanisms, Annoroad has formed distinctive technological advantages, providing excellent overall solutions for life science research.
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) founded in 2016. MGI is committed to building core tools and technologies that drive innovation in life science. MGI focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. MGI provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries.MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.